Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease

Phase 2

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Voxelotor

First Posted Date: 2016-08-01

Last Posted Date: 2024-11-14

Lead Sponsor: Pfizer

Target Recruit Count: 147

Registration Number: NCT02850406

Locations: 🇺🇸
Our Lady of the Lake Children's Hospital (IP Address), Baton Rouge, Louisiana, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States

and more 25 locations

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease

Phase 2

Terminated

Conditions: Parkinson Disease

Interventions: Drug: Placebo
Drug: PF-06649751

First Posted Date: 2016-07-28

Last Posted Date: 2020-11-23

Lead Sponsor: Pfizer

Target Recruit Count: 57

Registration Number: NCT02847650

Locations: 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸
Asheville Neurology Specialists PA, Asheville, North Carolina, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 34 locations

A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06463922
Drug: Itraconazole

First Posted Date: 2016-07-20

Last Posted Date: 2017-05-15

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT02838264

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain

Phase 3

Completed

Conditions: Pain

Interventions: Drug: FDC IBU/APAP 250 mg/500 mg
Drug: Placebo

First Posted Date: 2016-07-20

Last Posted Date: 2018-03-05

Lead Sponsor: Pfizer

Target Recruit Count: 123

Registration Number: NCT02837952

Locations: 🇺🇸
Pharmaceutical Research Associates, Inc., Salt Lake City, Utah, United States

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Phase 2

Withdrawn

Conditions: Ovarian Cancer

Interventions: Drug: Talazoparib
Drug: Temozolomide

First Posted Date: 2016-07-18

Last Posted Date: 2018-09-18

Lead Sponsor: Pfizer

Registration Number: NCT02836028

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: CP-690,550
Drug: Placebo
Drug: Methotrexate

First Posted Date: 2016-07-13

Last Posted Date: 2019-12-04

Lead Sponsor: Pfizer

Target Recruit Count: 694

Registration Number: NCT02831855

Locations: 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States
🇺🇸
Phase III Clinical Research, Fall River, Massachusetts, United States
🇺🇸
Western Michigan University Homer Stryker MD, Kalamazoo, Michigan, United States

and more 129 locations

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Conditions: Neoplasms
Carcinoma, Non-Small-Cell Lung

First Posted Date: 2016-07-06

Last Posted Date: 2017-07-21

Lead Sponsor: Pfizer

Registration Number: NCT02824094

Locations: 🇯🇵
Hyogo Cancer Center, Akashi, Hyogo, Japan
🇯🇵
Aichi cancer center central hospital, Nagoya, Aichi, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

and more 1 locations

A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06463922
Drug: rifampin

First Posted Date: 2016-06-17

Last Posted Date: 2019-01-25

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT02804399

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: PF-06751979 multiple ascending dose
Drug: PF-06751979 single dose
Drug: PF-06751979 multiple dose
Drug: Placebo multiple ascending dose
Drug: Placebo single dose
Drug: Placebo multiple elderly dose

First Posted Date: 2016-06-08

Last Posted Date: 2018-09-17

Lead Sponsor: Pfizer

Target Recruit Count: 46

Registration Number: NCT02793232

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive

Completed

Conditions: Severe Vasomotor Symptom Associated With Menopause

First Posted Date: 2016-06-07

Last Posted Date: 2021-08-05

Lead Sponsor: Pfizer

Target Recruit Count: 669

Registration Number: NCT02792504

Locations: 🇰🇷
Kyungpook National University/Department of Internal Medicine (Cardiology), Jung-gu, Daegu, Korea, Republic of
🇰🇷
Obstetrics / Grace Women's Hospital, Goyong-si, Ilsandong-gu, Korea, Republic of
🇰🇷
Dr. Wang's OB & GY Clinic, Seoul, Dobong-gu, Korea, Republic of

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy